Literature DB >> 15998219

Role of adult mesenchymal stem cells in bone tissue engineering applications: current status and future prospects.

Joshua R Mauney1, Vladimir Volloch, David L Kaplan.   

Abstract

Mesenchymal stem cells (MSCs) have been demonstrated as an attractive cell source for tissue-engineering applications because of their ability to be easily isolated and expanded from adult bone marrow aspirates and their versatility for pluripotent differentiation into mesenchymal tissues. This review highlights advances and progress in bone reconstruction techniques for both the repair of site-specific bone defects and the attenuation of musculoskeletal disease symptoms associated with osteoporosis and osteogenesis imperfecta. Despite the enormous potential benefits of MSCs within these approaches, conventional tissue culture methods limit the clinical utility of these cells because of the gradual loss of both their proliferative and differentiation potential during ex vivo expansion. Novel strategies to overcome these limitations are discussed including cultivation in the presence of basic fibroblastic growth factor 2, induction of ectopotic telomerase expression, and ex vivo expansion on various collagenous biomaterials. In addition, this review also outlines mechanistic theories on the potential role of MSC-extracellular matrix interactions in mediating the retention of MSC proliferative and differentiation capacity after ex vivo expansion on collagenous biomaterials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15998219     DOI: 10.1089/ten.2005.11.787

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  64 in total

1.  A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo.

Authors:  Shannon H Carroll; Nathan A Wigner; Nitin Kulkarni; Hillary Johnston-Cox; Louis C Gerstenfeld; Katya Ravid
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  Chitosan enhances mineralization during osteoblast differentiation of human bone marrow-derived mesenchymal stem cells, by upregulating the associated genes.

Authors:  S Mathews; P K Gupta; R Bhonde; S Totey
Journal:  Cell Prolif       Date:  2011-10-20       Impact factor: 6.831

3.  New biomaterials for bone regeneration.

Authors:  Fabrizio Matassi; Lorenzo Nistri; Diana Chicon Paez; Massimo Innocenti
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

Review 4.  Cell-based approaches to the engineering of vascularized bone tissue.

Authors:  Rameshwar R Rao; Jan P Stegemann
Journal:  Cytotherapy       Date:  2013-08-31       Impact factor: 5.414

Review 5.  Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases.

Authors:  Jakob Reiser; Xian-Yang Zhang; Charles S Hemenway; Debasis Mondal; Leena Pradhan; Vincent F La Russa
Journal:  Expert Opin Biol Ther       Date:  2005-12       Impact factor: 4.388

6.  Mesenchymal stem cells and tissue engineering.

Authors:  Nicholas W Marion; Jeremy J Mao
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

Review 7.  Cord-blood mesenchymal stem cells and tissue engineering.

Authors:  Curtis L Cetrulo
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

8.  Experimental characterization and computational modelling of two-dimensional cell spreading for skeletal regeneration.

Authors:  Bram G Sengers; Colin P Please; Richard O C Oreffo
Journal:  J R Soc Interface       Date:  2007-12-22       Impact factor: 4.118

9.  Semaphorin 3A promotes osteogenic differentiation in human alveolar bone marrow mesenchymal stem cells.

Authors:  Li Liu; Jue Wang; Xiaomeng Song; Qingping Zhu; Shuping Shen; Wei Zhang
Journal:  Exp Ther Med       Date:  2018-01-30       Impact factor: 2.447

10.  Multifunctionalized electrospun silk fibers promote axon regeneration in central nervous system.

Authors:  Corinne R Wittmer; Thomas Claudepierre; Michael Reber; Peter Wiedemann; Jonathan A Garlick; David Kaplan; Christophe Egles
Journal:  Adv Funct Mater       Date:  2011-11-16       Impact factor: 18.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.